Skip to main
MMED

MMED Stock Forecast & Price Target

MMED Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Minimed Group is a leader in the insulin delivery industry with a strong global presence and promising product pipeline. However, risks such as competition and regulatory challenges may impact future growth. Concerns about product design and ease of use may also affect the company's parent company, Medtronic. With a neutral rating and price target of $16, the company's focus on advanced algorithms and partnerships for growth may lead to increased revenue, but uncertainties and potential delays could hinder their success.

Bears say

Minimed Group is facing intense competition in the diabetes market, which may limit its pricing power and compress margins as it strives to offer economically attractive solutions. There is also a risk that payors may limit reimbursement or negotiate for tighter discounts as Minimed's technologies become more widely adopted. Additionally, the company has a history of struggling to meet product development timelines, which could leave it behind faster-moving competitors. With a highly competitive legacy insulin pump market and strong competition in the continuous glucose monitoring space, Minimed faces the challenge of maintaining its market share and competing against larger players with established devices and brand loyalty.

MMED has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiniMed Group Inc (MMED) Forecast

Analysts have given MMED a Buy based on their latest research and market trends.

According to 10 analysts, MMED has a Buy consensus rating as of Jul 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiniMed Group Inc (MMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.